# China NMPA Drug Inspection - 11 manufacturing companies (preparation units) - A total of 14 batches of 5 varieties of drugs

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/11-manufacturing-companies-preparation-units/ee7212d4-ba2b-49af-80ee-f9d0e8df4687/
Source feed: China

> China NMPA drug inspection for 11 manufacturing companies (preparation units) published September 25, 2020. Drug: A total of 14 batches of 5 varieties of drugs. In September 2020, the Shandong Provincial Drug Administration issued Announcement No. 19, detailing the results of its 

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Shandong Provincial Drug Administration's Drug Quality Sampling Inspection Announcement (Issue 6, 2020)
- Company Name: 11 manufacturing companies (preparation units)
- Publication Date: 2020-09-25
- Drug Name: A total of 14 batches of 5 varieties of drugs
- Inspection Finding: The sampled product did not meet the required standards.
- Action Taken: Relevant drug regulatory authorities have taken control measures such as sealing, seizing, suspending sales, and recalling products that do not meet the regulations, and have dealt with the relevant manufacturers (preparation units) and sampled units seriously in accordance with relevant laws and regulations.
- Summary: In September 2020, the Shandong Provincial Drug Administration issued Announcement No. 19, detailing the results of its sixth drug quality sampling inspection for the year. This regulatory initiative, conducted under the administration's annual safety plan, evaluated pharmaceutical products across production, distribution, and usage sectors. The inspection identified 14 non-compliant drug batches involving five varieties produced by 11 different manufacturers and preparation units. Key violations centered on three areas: failures in physical property standards (often due to incorrect material species or improper storage), identification discrepancies affecting authenticity, and inadequate active ingredient levels during content determination. To address these risks, the regulatory body enforced immediate control measures, including sealing and seizing non-compliant stock, suspending sales, and initiating product recalls. The involved companies were subjected to severe penalties as dictated by pharmaceutical laws. Furthermore, the administration mandated that all affected enterprises conduct internal investigations to identify the root causes of these failures and implement comprehensive rectification measures to ensure future product safety and compliance with medicinal standards.

Company: https://www.globalkeysolutions.net/companies/11-manufacturing-companies-preparation-units/1c522803-9df1-4b7c-96d1-48f17df16960/